EP4021904C0 - ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES - Google Patents
ALPHA-D-GALACTOPYRANOSIDE DERIVATIVESInfo
- Publication number
- EP4021904C0 EP4021904C0 EP20775188.4A EP20775188A EP4021904C0 EP 4021904 C0 EP4021904 C0 EP 4021904C0 EP 20775188 A EP20775188 A EP 20775188A EP 4021904 C0 EP4021904 C0 EP 4021904C0
- Authority
- EP
- European Patent Office
- Prior art keywords
- alpha
- galactopyranoside
- derivatives
- galactopyranoside derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/12—Triazine radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RS20240319A RS65294B1 (en) | 2019-08-29 | 2020-08-28 | Alpha-d-galactopyranoside derivatives |
| HRP20240297TT HRP20240297T1 (en) | 2019-08-29 | 2020-08-28 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2019073063 | 2019-08-29 | ||
| PCT/EP2020/074121 WO2021038068A1 (en) | 2019-08-29 | 2020-08-28 | Alpha-d-galactopyranoside derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP4021904A1 EP4021904A1 (en) | 2022-07-06 |
| EP4021904C0 true EP4021904C0 (en) | 2024-01-03 |
| EP4021904B1 EP4021904B1 (en) | 2024-01-03 |
Family
ID=72561746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20775188.4A Active EP4021904B1 (en) | 2019-08-29 | 2020-08-28 | Alpha-d-galactopyranoside derivatives |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US12319672B2 (en) |
| EP (1) | EP4021904B1 (en) |
| JP (1) | JP7612669B2 (en) |
| KR (1) | KR102824799B1 (en) |
| CN (1) | CN114585619B (en) |
| AU (1) | AU2020338816B2 (en) |
| BR (1) | BR112022003562A2 (en) |
| CA (1) | CA3148365A1 (en) |
| ES (1) | ES2972551T3 (en) |
| HR (1) | HRP20240297T1 (en) |
| HU (1) | HUE066221T2 (en) |
| IL (1) | IL290815B2 (en) |
| MA (1) | MA57000B1 (en) |
| MX (1) | MX2022002339A (en) |
| MY (1) | MY207787A (en) |
| PH (1) | PH12022550436A1 (en) |
| PL (1) | PL4021904T3 (en) |
| RS (1) | RS65294B1 (en) |
| SA (1) | SA522431777B1 (en) |
| TW (1) | TWI864085B (en) |
| UA (1) | UA129205C2 (en) |
| WO (1) | WO2021038068A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102863667B1 (en) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-acetamidyl)thio-beta-D-galactopyranoside derivatives |
| KR102854071B1 (en) | 2019-08-09 | 2025-09-02 | 이도르시아 파마슈티컬스 리미티드 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| BR112021026829A2 (en) | 2019-08-15 | 2022-02-22 | Idorsia Pharmaceuticals Ltd | Compound, pharmaceutical composition, use of a compound, and method for the prophylaxis or treatment of organ fibrosis; liver diseases and disorders; cardiovascular diseases and disorders; cell proliferative diseases and cancers; inflammatory and autoimmune diseases and disorders; diseases and disorders of the gastrointestinal tract; pancreatic diseases and disorders; diseases and disorders associated with abnormal angiogenesis; diseases and disorders associated with the brain; neuropathic pain and peripheral neuropathy; eye diseases and disorders; acute kidney injury and chronic kidney disease; interstitial lung diseases and disorders; or transplant rejection |
| MX2023004033A (en) | 2020-10-06 | 2023-04-27 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides. |
| KR20230104190A (en) | 2020-11-02 | 2023-07-07 | 이도르시아 파마슈티컬스 리미티드 | Galectin-3 inhibitory 2-hydroxycycloalkane-1-carbamoyl derivatives |
| ES3032987T3 (en) | 2021-02-09 | 2025-07-29 | Idorsia Pharmaceuticals Ltd | Hydroxyheterocycloalkane-carbamoyl derivatives |
| US20240109930A1 (en) * | 2021-03-03 | 2024-04-04 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0100172D0 (en) | 2001-01-22 | 2001-01-22 | Ulf Nilsson | New inhibitors against galectins |
| SE0401301D0 (en) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors or galectins |
| SE0401300D0 (en) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| CN104822382B9 (en) | 2012-10-10 | 2019-01-18 | 卡莱克汀医疗有限公司 | Galactose-branched carbohydrate compounds for the treatment of diabetic nephropathy and related diseases |
| IN2015DN02573A (en) | 2012-10-31 | 2015-09-11 | Galecto Biotech Ab | |
| CN104955471A (en) | 2012-11-15 | 2015-09-30 | 塔夫斯大学 | Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor |
| CN113621005B (en) * | 2015-01-30 | 2025-07-04 | 格莱克特生物技术公司 | α-D-galactoside inhibitors of galectins |
| HRP20190853T1 (en) | 2015-07-06 | 2019-06-28 | Gilead Sciences, Inc. | Cot modulators and methods of use thereof |
| US10889610B2 (en) | 2016-07-12 | 2021-01-12 | Galecto Biotech Ab | Alpha-D-galactoside inhibitors of galectins |
| MX392945B (en) | 2017-05-12 | 2025-03-19 | Galectin Sciences Llc | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND THEIR USE. |
| EP3621975A1 (en) | 2017-05-12 | 2020-03-18 | Galectin Sciences, LLC | Compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| US11267811B2 (en) | 2017-09-27 | 2022-03-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of galectin-3 |
| US11072626B2 (en) | 2017-10-11 | 2021-07-27 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| EP3707149A1 (en) | 2017-10-31 | 2020-09-16 | Galectin Sciences, LLC | Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof |
| WO2020078807A1 (en) | 2018-10-15 | 2020-04-23 | Galecto Biotech Ab | Prodrug of galactoside inhibitors of galectins |
| CA3113956A1 (en) | 2018-10-15 | 2020-04-23 | Galecto Biotech Ab | Galactoside inhibitor of galectins |
| JP7486484B2 (en) | 2018-11-21 | 2024-05-17 | ガレクト バイオテック エービー | Alpha-D-galactoside inhibitors of galectins |
| US12269819B2 (en) | 2019-04-10 | 2025-04-08 | Bristol-Myers Squibb Company | Small molecule inhibitors of Galectin-3 |
| CA3141436A1 (en) | 2019-07-03 | 2021-01-07 | Fredrik Zetterberg | Novel galactoside inhibitor of galectins |
| CN114450282A (en) | 2019-07-05 | 2022-05-06 | 格莱克特生物技术公司 | Novel galactoside inhibitors of galectins |
| KR102854071B1 (en) | 2019-08-09 | 2025-09-02 | 이도르시아 파마슈티컬스 리미티드 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives |
| KR102863667B1 (en) | 2019-08-09 | 2025-09-23 | 이도르시아 파마슈티컬스 리미티드 | (2-acetamidyl)thio-beta-D-galactopyranoside derivatives |
| BR112021026829A2 (en) | 2019-08-15 | 2022-02-22 | Idorsia Pharmaceuticals Ltd | Compound, pharmaceutical composition, use of a compound, and method for the prophylaxis or treatment of organ fibrosis; liver diseases and disorders; cardiovascular diseases and disorders; cell proliferative diseases and cancers; inflammatory and autoimmune diseases and disorders; diseases and disorders of the gastrointestinal tract; pancreatic diseases and disorders; diseases and disorders associated with abnormal angiogenesis; diseases and disorders associated with the brain; neuropathic pain and peripheral neuropathy; eye diseases and disorders; acute kidney injury and chronic kidney disease; interstitial lung diseases and disorders; or transplant rejection |
| MX2023004033A (en) | 2020-10-06 | 2023-04-27 | Idorsia Pharmaceuticals Ltd | Spiro derivatives of alpha-d-galactopyranosides. |
| KR20230104190A (en) | 2020-11-02 | 2023-07-07 | 이도르시아 파마슈티컬스 리미티드 | Galectin-3 inhibitory 2-hydroxycycloalkane-1-carbamoyl derivatives |
| ES3032987T3 (en) | 2021-02-09 | 2025-07-29 | Idorsia Pharmaceuticals Ltd | Hydroxyheterocycloalkane-carbamoyl derivatives |
| US20240109930A1 (en) | 2021-03-03 | 2024-04-04 | Idorsia Pharmaceuticals Ltd | Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives |
-
2020
- 2020-08-28 KR KR1020227009790A patent/KR102824799B1/en active Active
- 2020-08-28 EP EP20775188.4A patent/EP4021904B1/en active Active
- 2020-08-28 US US17/638,799 patent/US12319672B2/en active Active
- 2020-08-28 IL IL290815A patent/IL290815B2/en unknown
- 2020-08-28 CN CN202080060134.6A patent/CN114585619B/en active Active
- 2020-08-28 JP JP2022512854A patent/JP7612669B2/en active Active
- 2020-08-28 MA MA57000A patent/MA57000B1/en unknown
- 2020-08-28 ES ES20775188T patent/ES2972551T3/en active Active
- 2020-08-28 AU AU2020338816A patent/AU2020338816B2/en active Active
- 2020-08-28 PH PH1/2022/550436A patent/PH12022550436A1/en unknown
- 2020-08-28 TW TW109129635A patent/TWI864085B/en active
- 2020-08-28 CA CA3148365A patent/CA3148365A1/en active Pending
- 2020-08-28 PL PL20775188.4T patent/PL4021904T3/en unknown
- 2020-08-28 MX MX2022002339A patent/MX2022002339A/en unknown
- 2020-08-28 MY MYPI2022001043A patent/MY207787A/en unknown
- 2020-08-28 BR BR112022003562A patent/BR112022003562A2/en unknown
- 2020-08-28 UA UAA202201022A patent/UA129205C2/en unknown
- 2020-08-28 WO PCT/EP2020/074121 patent/WO2021038068A1/en not_active Ceased
- 2020-08-28 HR HRP20240297TT patent/HRP20240297T1/en unknown
- 2020-08-28 HU HUE20775188A patent/HUE066221T2/en unknown
- 2020-08-28 RS RS20240319A patent/RS65294B1/en unknown
-
2022
- 2022-02-27 SA SA522431777A patent/SA522431777B1/en unknown
-
2025
- 2025-04-29 US US19/193,332 patent/US20250257056A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114585619B (en) | 2024-09-27 |
| AU2020338816A1 (en) | 2022-04-14 |
| US20250257056A1 (en) | 2025-08-14 |
| US20220281855A1 (en) | 2022-09-08 |
| US12319672B2 (en) | 2025-06-03 |
| PL4021904T3 (en) | 2024-05-13 |
| SA522431777B1 (en) | 2024-04-30 |
| IL290815A (en) | 2022-04-01 |
| ES2972551T3 (en) | 2024-06-13 |
| HUE066221T2 (en) | 2024-07-28 |
| CN114585619A (en) | 2022-06-03 |
| WO2021038068A1 (en) | 2021-03-04 |
| EP4021904B1 (en) | 2024-01-03 |
| MY207787A (en) | 2025-03-19 |
| BR112022003562A2 (en) | 2022-05-24 |
| MA57000B1 (en) | 2024-03-29 |
| HRP20240297T1 (en) | 2024-05-10 |
| JP2022546029A (en) | 2022-11-02 |
| RS65294B1 (en) | 2024-04-30 |
| TW202122092A (en) | 2021-06-16 |
| KR102824799B1 (en) | 2025-06-24 |
| KR20220053622A (en) | 2022-04-29 |
| AU2020338816B2 (en) | 2026-01-08 |
| TWI864085B (en) | 2024-12-01 |
| UA129205C2 (en) | 2025-02-05 |
| MX2022002339A (en) | 2022-04-06 |
| IL290815B2 (en) | 2025-08-01 |
| EP4021904A1 (en) | 2022-07-06 |
| PH12022550436A1 (en) | 2022-12-19 |
| CA3148365A1 (en) | 2021-03-04 |
| IL290815B1 (en) | 2025-04-01 |
| JP7612669B2 (en) | 2025-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3958977T (en) | CAMPTOTECIN DERIVATIVES | |
| IL292161A (en) | New methylquinazolinone derivatives | |
| EP3994692C0 (en) | COMPUTE-IN-MEMORY BITZEL | |
| EP3833739A4 (en) | AKKOMANSIA MUCINIPHILA | |
| DK4067344T3 (en) | Cycloalkylurea derivative | |
| PL4013751T3 (en) | 2-HYDROXYCYCLOALKANE-1-CARBAMOYL DERIVATIVES | |
| LT3830085T (en) | DEUTERINED LANIFIBRANOR DERIVATIVES | |
| EP4077334C0 (en) | FUROINDAZOLE DERIVATIVES | |
| DK3768669T3 (en) | Piperazinazaspiro derivatives | |
| EP4021904C0 (en) | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | |
| EP3930851A4 (en) | POLYTHERAPIES | |
| EP3919491C0 (en) | Act-inhibitor | |
| IL288173A (en) | Sonosensitization | |
| EP3742771C0 (en) | M2M-SM-SR- TO -SM-DP-NOTIFICATION | |
| EP3967649C0 (en) | LIPIDNANOPARTICLES | |
| DK3823970T3 (en) | FURTHER SUBSTITUTED TRIAZOLOQUINOXALINE DERIVATIVES | |
| DK3823971T3 (en) | SUBSTITUTED TRIAZOLE-QUINOXALINE DERIVATIVES | |
| EP3912517C0 (en) | MOLDURA | |
| EP3975220A4 (en) | SHOWBOARD | |
| DK3796975T3 (en) | SULFONYLAMINOBENZAMIDE DERIVATIVES | |
| EP3973348A4 (en) | VISIO-HEADS | |
| EP3957391C0 (en) | STIR-ERS | |
| EP3965638C0 (en) | VAGINALSPECULUM | |
| EP3962498A4 (en) | POLYTHERAPIES | |
| DK3894410T3 (en) | SUBSTITUTED XANTHIND DERIVATIVES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: TUEP Ref document number: P20240297T Country of ref document: HR |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220329 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40072885 Country of ref document: HK |
|
| DAX | Request for extension of the european patent (deleted) | ||
| RAV | Requested validation state of the european patent: fee paid |
Extension state: TN Effective date: 20220329 Extension state: MA Effective date: 20220329 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20230316 |
|
| GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTC | Intention to grant announced (deleted) | ||
| INTG | Intention to grant announced |
Effective date: 20230724 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602020023877 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| U01 | Request for unitary effect filed |
Effective date: 20240201 |
|
| U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20240209 |
|
| REG | Reference to a national code |
Ref country code: MA Ref legal event code: VAGR Ref document number: 57000 Country of ref document: MA Kind code of ref document: B1 |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: T1PR Ref document number: P20240297 Country of ref document: HR |
|
| REG | Reference to a national code |
Ref country code: SK Ref legal event code: T3 Ref document number: E 43820 Country of ref document: SK |
|
| REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20240400807 Country of ref document: GR Effective date: 20240516 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2972551 Country of ref document: ES Kind code of ref document: T3 Effective date: 20240613 |
|
| REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E066221 Country of ref document: HU |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20240297 Country of ref document: HR Payment date: 20240819 Year of fee payment: 5 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602020023877 Country of ref document: DE |
|
| U20 | Renewal fee for the european patent with unitary effect paid |
Year of fee payment: 5 Effective date: 20240902 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240103 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20240103 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| 26N | No opposition filed |
Effective date: 20241007 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: HU Payment date: 20250825 Year of fee payment: 6 |
|
| REG | Reference to a national code |
Ref country code: HR Ref legal event code: ODRP Ref document number: P20240297 Country of ref document: HR Payment date: 20250815 Year of fee payment: 6 |
|
| U20 | Renewal fee for the european patent with unitary effect paid |
Year of fee payment: 6 Effective date: 20250901 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20250926 Year of fee payment: 6 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NO Payment date: 20250826 Year of fee payment: 6 Ref country code: MC Payment date: 20250822 Year of fee payment: 6 Ref country code: GR Payment date: 20250822 Year of fee payment: 6 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20250819 Year of fee payment: 6 Ref country code: PL Payment date: 20250816 Year of fee payment: 6 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20250820 Year of fee payment: 6 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: HR Payment date: 20250815 Year of fee payment: 6 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20250901 Year of fee payment: 6 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CZ Payment date: 20250818 Year of fee payment: 6 Ref country code: RS Payment date: 20250815 Year of fee payment: 6 Ref country code: IE Payment date: 20250820 Year of fee payment: 6 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: RO Payment date: 20250818 Year of fee payment: 6 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SK Payment date: 20250818 Year of fee payment: 6 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IS Payment date: 20250812 Year of fee payment: 6 |
|
| VSFP | Annual fee paid to validation state [announced via postgrant information from national office to epo] |
Ref country code: MA Payment date: 20250819 Year of fee payment: 6 Ref country code: MA Payment date: 20240819 Year of fee payment: 5 |
|
| U1N | Appointed representative for the unitary patent procedure changed after the registration of the unitary effect |
Representative=s name: KOBERSTEIN, RALF; CH |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CY Payment date: 20250722 Year of fee payment: 6 |